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ABSTRACT
Objective: The plant mahkota dewa (Phaleria macrocarpa) is known to have anti-inflammatory effects. This study aimed to determine whether 
chitosan nanoparticles containing mahkota dewa leaf extract would yield superior anti-inflammatory effects in the colon of a mouse model of dextran 
sodium sulfate (DSS)-induced ulcerative colitis, compared with ethanol extract alone after testing the acute toxicities (lethal dose) of both preparations.
Methods: For acute toxicity testing, 10 Sprague-Dawley rats were administered 6000 mg/kg body weight (BW) of leaf extract alone or with nanoparticles. 
Subsequently, mice were divided into the following six groups to determine the anti-inflammatory effects: Untreated, negative control (DSS 2% w/v), leaf 
extract at 12.5 or 25 mg/kg BW, and leaf extract in chitosan nanoparticles at 6.25 or 12.5 mg/kg BW. To induce colitis, DSS (2% w/v) was administered 
through drinking water for 6 weeks. The anti-inflammatory effect was observed histopathologically by imaging the inflammatory cells of the mice colon 
with hematoxylin-eosin (HE) staining.
Results: For acute toxicity testing, 10 Sprague-Dawley rats were administered 6000 mg/kg BW of leaf extract alone or with nanoparticles. Subsequently, 
mice were divided into the following six groups to determine the anti-inflammatory effects: Untreated, negative control (DSS 2% w/v), leaf extract at 
12.5 or 25 mg/kg BW, and leaf extract in chitosan nanoparticles at 6.25 or 12.5 mg/kg BW. To induce colitis, DSS (1% w/v) was administered through 
drinking water for 6 weeks. The anti-inflammatory effect was observed histopathologically by imaging the inflammatory cells of the mice colon with 
HE staining.
Conclusion: Chitosan nanoparticles containing mahkota dewa leaf extract can be included in the practically non-toxic class of materials. However, an 
ethanol extract of mahkota dewa leaf effectively inhibited DSS-induced inflammation in the mouse colon, regardless of delivery vehicle.
Keywords: Mahkota dewa leaf extract, Chitosan nanoparticles, Acute toxicity, Inflammation, Histopathology.
INTRODUCTION
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD) 
characterized by chronic inflammation of the large intestinal mucosal 
layer. Patients with chronic UC face a high risk of colorectal cancer 
development within 10–30 years [1-4]. To date, UC has been treated 
through surgical procedures and corticosteroid and 5-aminosalicylic 
acid therapy. Although drug therapy may reduce inflammation, the 
effect may be short-lived and the patient can experience a relapse. The 
currently available drugs can also cause serious side effects, such as 
gastric ulcers and gastrointestinal bleeding.
Several studies have investigated the use of natural and apparently safe 
ingredients for the prevention and treatment of UC. One such ingredient, 
the plant mahkota dewa (Phaleria macrocarpa) [5,6], contains flavonoid 
compounds such as kaempferol and quercetin, and an extract of the leaves 
has been shown to exert anti-inflammatory effects by suppressing the 
activity of nuclear factor kappa beta (NF-κB), cyclooxygenase (COX)-2 and 
inducible nitric oxide synthase (iNOS) [7-9]. In a study by Suprapti et al., a 
25 mg dose of mahkota dewa leaf extract was shown to reduce the levels of 
iNOS, β-catenin, and COX-2, although a high-dose extract was fatal to some 
animals; accordingly, the survival rate was <100%. This mortality was 
attributed to the lethal effects of extract components on other organs [10].
The oral administration of mahkota dewa leaf extract is expected to 
suppress the activity of specific inflammatory proteins in the colon. 
However, this method of administration is also expected to be affected 
by gastrointestinal absorption, particularly in the stomach and small 
intestine, before the compound reaches its target in the colon [7-9]. 
Therefore, a more colon-specific delivery has been investigated to 
ensure that the extract reaches its target and produces the desired effect.
One rational option for extract delivery involves packing the extract 
in the form of chitosan nanoparticles. Allegedly, this format will allow 
delivery of the compound to the colon followed by release from the 
nanoparticles. The nano-scale size is thought to facilitate the diffusion 
of the extract into cells in the colon, where it will target inflammatory 
proteins. In addition, a more targeted delivery method could reduce 
the dose required to yield anti-inflammatory effects [11-13]. In this 
study, we will investigate the effects of a mahkota dewa leaf extract 
delivered through chitosan nanoparticles on colonic inflammation in a 
mouse model of dextran sodium sulfate (DSS)-induced UC. Particularly, 
we will evaluate the histopathology of the gastrointestinal organs, 
especially the colon, using hematoxylin-eosin (HE) staining to visualize 
morphologic changes. This type of staining is very useful for identifying 
the morphologic and cellular components of organs and facilitating the 
diagnosis of histopathological abnormalities [14,15].
We note that herbal preparations are required to undergo safety testing. 
Therefore, this study also evaluated the acute toxicities (lethal dose [LD50]) 
of the mahkota dewa leaf extract delivered alone or within chitosan 
nanoparticles before the mouse model experiment. Acute oral toxicity 
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testing aims to determine the intrinsic toxicity of a substance, target organ, 
and species sensitivity. It is also used to obtain hazard information after acute 
exposure, preliminary information that can be used to establish the dose 
rate and subsequent toxicity tests and identify the LD50 values of materials 
and preparations. Finally, such testing determines the classifications of 
materials and preparations, as well as the labeling information.
METHODS
This experimental study featured a completely randomized design. The 
research was conducted in 2017 at the Animal Laboratory of Center 
for Health Research and Development, Ministry of Health, Jakarta with 
the approval of the Health Research Ethics Committee of the Faculty of 
Medicine Universitas Indonesia (approval no. 17/2/UN2.F1/ETIK/2017).
Oral acute toxicity test
Experimental animals
Female Sprague-Dawley rats aged 8–12 weeks with body weights (BWs) of 
≥120 g were used for the acute oral acute toxicity test. The animals were 
housed in a facility in which the temperature, humidity, light, and noise 
levels were maintained to ensure a healthy environment. The rats were 
provided with food and water ad libitum according to laboratory standards.
Reagents
Two forms of an ethanol extract of P. macrocarpa leaf were tested: 
Alone and delivered in chitosan nanoparticles. The ethanol extract 
was obtained from the Laboratory of IPB Biopharmaceutical Study 
Center (Bogor), and the nanoparticles were produced at PT Nanotech 
Indonesia (Puspiptek-Tangerang).
Testing follows the principle that the administration of a single dose of an 
orally tested agent may exhibit toxic effects. Therefore, the test preparations 
were administered at a single dose of 6000 mg/kg BW because the 
traditional medicinal extract of P. macrocarpa, which is considered relatively 
safe (non-toxic), has a single dose limit of 5000 mg/kg BW.
For the experiment, 10 rats were divided into two groups of five rats (one for 
preliminary testing and four additional animals). Group I directly received 
the ethanol extract of P. macrocarpa leaf, while Group II received the same 
extract delivered in chitosan nanoparticles. All rats were acclimated for at 
least 5 days before treatment. Before receiving the test preparation, the rats 
were fasted for 14–16 h (water was provided), weighed and administered 
the test preparation dissolved in water using sonde.
Observational analysis
Observations of the skin, fur, eyes, mucous membranes, respiratory 
system, autonomic nervous system, central nervous system, 
somatomotor activity, and behavior were made immediately and within 
30 min and 4 h after test preparation administration followed by every 
24 h for 14 days. The BWs of the rats were recorded every 2 days. Dead 
mice were also subjected to observational analyzes, and all surviving 
mice were sacrificed and subjected to autopsy and macroscopic 
observations at the end of the study. Histopathology examinations were 
conducted if suspicious findings were observed.
For a tested substance, a smaller LD50 level indicates greater toxicity 
[16-19]. For medicines and other traditional ingredients (e.g., foodstuffs), 
acute toxicity categories in mice are stratified as follows: very toxic, 
oral LD50≤1 mg/kg BW; toxic, oral LD50=1–50 mg; medium toxicity, 
oral LD50=50–500 mg; light toxicity, LD50=500–5000 mg; practically 




Swiss Webster mice aged approximately 12 weeks with an average 
BW of 25 g were acclimated for 1 week before treatment. The mice 
were obtained from the Animal Laboratory of the Center for Health 
Research and Development, Ministry of Health, Jakarta, and maintained 
in accordance with the Guidelines for the Treatment and Use of Animal 
Laboratories of the Animal Committee. This research was approved 
by the Medical Research Ethics Committee of the Faculty of Medicine, 
University of Indonesia. The mice were housed in an environment with 
a controlled temperature of 25°C, 55% humidity, and a 12-light/dark 
cycle. All mice were provided standard feed and water ad libitum.
Thirty-six mice were divided into six groups to receive the following 
treatments (Fig. 1):
1. N=No treatment.
2. KN=Negative control: DSS 2% w/v (administered in drinking water 
for 1 week beginning on week 1, followed by no DSS for 1 week; this 
was repeated for up to 3 DSS cycles).
3. Ext MD 25 mg=Treatment 1: DSS 2% w/v as described 
above+P. macrocarpa leaf extracts 25 mg/kg BW given orally for 5 
weeks, beginning on week.
4. Ext MD 12.5 mg=Treatment 2: DSS 2% w/v+P. macrocarpa extracts 
12.5 mg/kg BW administered as described for Group III.
5. NPMD 12.5 mg=Treatment 3: DSS 2% w/v+P. macrocarpa leaf 
extracts 12.5 mg/kg BW in chitosan nanoparticles administered 
orally for 5 weeks, beginning on week 3.
6. NPMD 6.25 mg=Treatment 4: DSS 2% w/v+P. macrocarpa leaf 
extracts 6.25 mg/kg BW in chitosan nanoparticles administered as 
described for Group V.
Sample preparation
The mice were sacrificed in the 7th week through cervical dislocation. 
Colon tissues were harvested, cleaned, and rinsed with water. Tissue 
pieces were fixed in a 10% formalin buffer for 24–48 h, dehydrated, 
cleared in a stratified xylol solution and infiltrated with paraffin using 
an automatic tissue processor. Subsequently, the tissue was embedded 
into paraffin medium in a labeled block cassette. Prepared paraffin 
blocks were sliced using a microtome to yield slices with thicknesses of 
3–5 ìm. The slices were placed in a water bath (40 °C–50 °C), affixed to 
glass slides and dried at 40 °C for 1 h.
HE staining
The processed tissue sections were immersed in xylol I and xylol II 
for 5 min each, and subsequently regraded in an ethanol gradient 
series (100%, 90%, and 75%) for 5 min per step. Subsequently, the 
preparations were stained by dipping into a hematoxylin solution for 
5–10 min followed by a wash under running water for 5–10 min. The 
sections were then immersed in a solution of lithium carbonate followed 
by another wash under running water for 5–10 min. Finally, the samples 
were dipped into an eosin solution for 1–3 min. The next process of 
dehydration by dipping into the alcohol the concentration increases, 
Fig. 1: Research flow chart
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that is, 70%, 90%, and 100% each ×3–4 dye. After re-dehydration, the 
sections were immersed into xylol I and xylol II solutions for 5 min each. 
Finally, the preparations were treated with 1 drop of Ingelan and covered 
with a glass coverslip.
Interpretation of HE staining
Mouse colon samples were subjected to a histopathologic examination 
using a Leica light microscope and Sigma microscope camera at ×400 
magnification. Five fields of view were obtained for each preparation, 
after which the assessment was done in accordance with a 2015 report 
by Rogers et al. in which each preparation was scored according to 
severity, extent, and inflammation as shown in Table 1.
Data analysis
The data distributions were analyzed using the Shapiro–Wilk test, 
followed by a one-way analysis of variance and Tukey’s test. Non-
homogeneously distributed data were analyzed non-parametrically 
using the Kruskal–Wallis test.
RESULTS AND DISCUSSION
Oral acute toxicity test
No adverse effects such as seizures, tremors, salivation, diarrhea, 
lethargy, weakness, sleep disorders, or coma were observed in the 
rats within 4 h of treatment with P. macrocarpa leaf extract delivered 
directly or through chitosan nanoparticles. Nor are there any animals 
did not hide or crawl on their bellies. No deaths or symptoms of 
toxicity were observed in either group after 14 days. The weights 
of rats in both groups during the 14-day observation period are 
presented in Figs. 2 and 3. After 14 days, all animals were sacrificed. 
Necropsy revealed no gross pathology in any test animals; therefore, no 
microscopic examination was performed.
Histopathological results
Both modes of P. macrocarpa leaf extract were found to reduce inflammation 
induced by DSS. Notably, a significant difference in inflammation was 
detected between normal group (1.33), Dewa leaf extract 25 mg/kg 
BB (Ext MD 25 mg) (2.1), leaf extract P. macrocarpa 12.5 mg/kg BB 
(Ext MD 12.5 mg) (1.633), leaf extract of P. macrocarpa in nano chitosan 
particle 12.5 mg/kg BB (NPMD 12.5 mg) (1.633), and P. macrocarpa leaf 
extract in nano chitosan particle 6.25 mg/kg BB (NPMD 6.25 mg) (1.697) 
compared with the negative control group (3.33) (p<0.05) (Fig. 4). No 
significant differences were observed between the two forms of extract.
DISCUSSION
Our oral acute toxicity testing results indicated that the mixture of 
chitosan nanoparticles and P. macrocarpa leaf extract could be classified 
as a PNT material, as the test preparation did not cause adverse effects 
or death at a dose >5000 mg/kg BW. Therefore, a human could safely 
consume a dose of either preparation up to 5000 mg/kg BW [19].
Previous research has determined that the P. macrocarpa leaf extract 
contains flavonoids [7], which are thought to exert several mechanisms 
such as antioxidative effects, direct free radical capture, leukocyte 
immobilization, and interactions with enzyme systems [20]. In this 
study, we induced UC using DSS, a polyamine dextran known to impair 
gastrointestinal permeability and interfere with the colonic mucosal 
barrier function, thus causing cellular damage and further triggering an 
immune response. DSS is a common means of inducing acute and chronic 
UC in animals [21]. In this study, 3 cycles of 2% DSS administration 
for 7 days, followed by 7 days with no administration, were applied 
according to reports by Zhang [21]. In this study, we employed targeted 
drug delivery through using nanoparticles, which were expected to in 
the increase drug concentration, and therefore efficacy, in the desired 
tissue through passive targeting while minimizing drug delivery to 
non-target tissues. Nanoparticles, which comprise colloidal polymer 
particles or solids, have diameters of 10–1000 nm and can be used 
in targeted delivery systems to improve bioavailability and control 
the drug release. Natural materials such as chitosan and Na TPP are 
commonly used as conductors; the positive charge of the chitosan amine 
group interacts with the negative charge of TPP to form complexes 
with sizes in the nanoparticle range [22]. Medical applications usually 
involve nanoparticle sizes <200 nm (microcapillary width), and drugs 
are applied to or dissolved, captured, embedded, and/or encapsulated 
into the nano matrix. The properties and characteristics of the release 
Fig. 2: Changes in body weight of rats who received the Phaleria 
macrocarpa leaf extract on an acute oral toxicity test (in 14 days)
Fig. 3: Changes in body weight of rats who received the Phaleria 
macrocarpa leaf extract in chitosan nanoparticle on an acute oral 
toxicity test (in 14 days)
Table 1: Inflammatory scoring according to Rogers et al.
Score Measurement criteria
0 Healthy colon
1 Minimal inflammation with minimal to no separation of 
crypts (generally focal affecting<10% of mucosa)
2 Mild inflammation with mild separation of 
crypts (generally affecting 11–25% of mucosa or mild, 
diffuse inflammatory infiltrates with minimal separation 
of crypts)
3 Moderate inflammation with separation of crypts, with 
or without focal effacement of crypts (generally affecting 
26–50% of mucosa or moderate, diffuse separation of 
crypts)
4 Extensive inflammation with marked separation and 
effacement of crypts (generally affecting 51–75% of 
mucosa)
5 Diffuse inflammation with marked separation and 
effacement of crypts (generally affecting>75% of mucosa)
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of the active substance can be adjusted depending on the manufacturing 
method [13].
Our study results indicate no significant differences between the ethanol 
extract of P. macrocarpa leaf administered alone and delivered in 
chitosan nanoparticles in terms of the ability to inhibit inflammation in 
the mouse model colon. We attribute this to the size of the nanoparticles, 
which exceeded 200 nm. Our histopathologic observations of HE-stained 
colon tissues were assessed using the scoring criteria developed by 
Rogers et al. [23]. The administration of 2% DSS with molecular weight 
60,000 (60 kDa) yielded significant inflammatory characteristics. These 
results are consistent with previous findings by Perse and Cerar, who 
reported that the molecular weight of DSS is a very important factor 
in colitis induction [24]. Notably, both forms of the P. macrocarpa leaf 
extract significantly decreased the inflammatory scores, possibly 
due to the effects of flavonoids such as kaempferol, which has anti-
inflammatory effects in vitro and in silico by inhibiting of NF-κB 
activity [25]. Specifically, kaempferol has the same binding energy and 
docking position as the NF-κB inhibitor. The transcription factor NF-κB 
is activated by various stimuli, including lipopolysaccharides from 
bacterial cell walls. In addition, kaempferol may inhibit the endothelial 
adhesion molecule intercellular adhesion molecule-1 (ICAM-1), which 
is upregulated during inflammation and facilitates the recruitment, 
migration, and activation of T lymphocytes, by inhibiting the expression 
of both ICAM-1 mRNA and proteins. Accordingly, the migration and 
activation of T cells would be inhibited [25].
Histopathologic observations revealed that the untreated group of mice 
also exhibited inflammation, with an average score of 1.33. This was 
attributed to environmental factors, such as food and drinking water, which 
are suspected to cause inflammation in the colon [26,27]. A previous study 
showed that foods with a high-fat content may increase the risk of IBD by 
modulating Toll-like receptors on macrophages [26]. Furthermore, high 
iron levels in drinking water can trigger IBD by stimulating the growth of 
inflammation-causing bacteria in the colon [27].
Black and red arrows indicate goblet cells and inflammation, 
respectively (Fig. 5).
CONCLUSION
P. macrocarpa leaf extract, administered directly or in chitosan 
nanoparticles, can be classified as a PNT material according to the 
results of the safety analysis. Furthermore, both means of leaf extract 
delivery equally and significantly reduced the inflammatory scores in a 
DSS-treated mouse model of UC, compared to the negative control. We, 
therefore, conclude that the ethanol extract and chitosan nanoparticle 
forms of P. macrocarpa leaf administration are equally effective 
inhibitors of DSS-induced inflammation in the mouse colon.
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